Skip to main content
OpenTrials
Completed

NCT Number: NCT01647867

Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers

Our project, established through collaboration between clinicians (Oscar Lambret Center-University Hospital) and scientists (IBL), aims to evaluate the expression of Met fragments in the lung cancer (LC). Unlike previous studies on Met by sequencing, in situ hybridization or immunohistochemistry, the investigators propose a protein analysis by Western blot of tumor samples and healthy tissue. This approach will evaluate the expression of full-length receptor, the potential presence of intracellular fragments, and their phosphorylation status.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non Small Cell Lung Cancer Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier Régional et Universitaire, Lille, France

Loading trial locations.

About this study

  • Patient information and collection of signed inform consent
  • Blood sample collection before bronchoscopy or before surgery, at the same time as a usual blood assessment.
  • Prospective collection of bronchial biopsies of patients with metastatic non small cell lung cancer, during a bronchoscopy at the Oscar Lambret Center (Dr Dansin)
  • Prospective collection of resected specimens of patients with localized non small cell lung cancer, who were operated at the thoracic surgery unit of the University hospital (Pr Porte)
  • Transportation of the samples to the pathology laboratories (Dr Robin, Pr Copin)
  • Selection of blocks of interest and preparation of tumor samples
  • Clinical data collection : date of biopsy or surgery, disease-free survival, overall survival, tumor characteristics, EGFR status, ALK, BRAF, HER2
  • Transportation of tumor blocks and blood samples to the Institute of Biology of Lille for analyses: Western blot, immunohistochemistry and ELISA test)
  • Return to storage of the tumor samples at the Oscar Lambret Center and at the University hospital of Lille

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with non small cell lung cancer (NSCLC)
  • Patients candidate for bronchial biopsies at the Oscar Lambret Center (metastatic stage) or candidate for thoracic surgery at University Hospital of Lille (localized stage)
  • Treatment naive patient for metastatic NSCLC
  • Patients with or without neoadjuvant therapy for localized NSCLC
  • Male or female patients aged ≥ 18 years
  • Patient registered with the social security system
  • Having signed a written Informed Consent

Exclusion criteria

  • Malignant tumors which are not carcinoma
  • Small-cell malignant tumors
  • Secondary bronchial lesions
  • Revision surgery
  • Pregnant or breastfeeding women
  • Patient under guardianship or tutorship
  • Previous cancer

Treatment and study plan

Met analysis on tissue and blood

Other

10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease

Primary outcomes

  1. Expression and localization of Met C-terminal active fragments in NSCLC

    Time frame: baseline

    Western Blot and immunohistochemistry

Secondary outcomes

  1. Evaluation of the activation of Met receptor

    Time frame: baseline

    Activation of Met receptor by immunochemical analysis (Western Blot)

  2. Correlation between expression of Met receptor fragments with clinical characteristics and/or prognosis factors as sex, TNM, EGFR status, histology, smoking status, survival

    Time frame: baseline

    Relationships between Met receptor expression and sex, TNM, EGFR status, histology, smoking status, survival

  3. Expression in plasma of N-terminal Met fragments

    Time frame: baseline

    ELISA test

Sponsors and collaborators

Lead sponsor

Centre Oscar Lambret

Other

Registry information

Acronym: MetLung

Important dates

Study start
2012
Primary completion
2015
Study completion
2016
First posted
Jul 24, 2012
Registry last updated
Mar 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.